Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CHRO
Upturn stock ratingUpturn stock rating

Chromocell Therapeutics Corporation (CHRO)

Upturn stock ratingUpturn stock rating
$1.08
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/04/2025: CHRO (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $8.5

1 Year Target Price $8.5

Analysts Price Target For last 52 week
$8.5Target price
Low$0.45
Current$1.08
high$3.8

Analysis of Past Performance

Type Stock
Historic Profit 83.33%
Avg. Invested days 71
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 5.0
Stock Returns Performance Upturn Returns Performance 4.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/04/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 8.90M USD
Price to earnings Ratio -
1Y Target Price 8.5
Price to earnings Ratio -
1Y Target Price 8.5
Volume (30-day avg) 1
Beta -
52 Weeks Range 0.45 - 3.80
Updated Date 06/30/2025
52 Weeks Range 0.45 - 3.80
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.2

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -188.95%
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value 11276488
Price to Sales(TTM) -
Enterprise Value 11276488
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -3.58
Shares Outstanding 6595850
Shares Floating 2561300
Shares Outstanding 6595850
Shares Floating 2561300
Percent Insiders 53.87
Percent Institutions 13.6

Analyst Ratings

Rating 1
Target Price 8.5
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Chromocell Therapeutics Corporation

stock logo

Company Overview

overview logo History and Background

Chromocell Therapeutics Corporation is a biopharmaceutical company focusing on the discovery and development of novel therapeutics. It was founded in 2002. A key milestone was the development of its Chromovertu00ae technology, enabling the creation of cell-based assays for drug discovery. Over time, Chromocell has shifted its focus towards developing non-addictive pain therapeutics and flavor enhancers.

business area logo Core Business Areas

  • Drug Discovery and Development: Chromocell focuses on discovering and developing novel therapeutics, particularly in the area of pain management. It leverages its Chromovertu00ae technology for high-throughput screening and target identification.
  • Flavor and Scent Ingredient Discovery: Chromocell also develops and commercializes flavor and scent ingredients using its proprietary technology platform. This includes identifying and creating novel flavor compounds for the food and beverage industry.

leadership logo Leadership and Structure

Chromocell Therapeutics Corporation is a privately held company and has a Board of Directors that guides the CEO and executive team. Detailed organizational information and leadership structure are not publicly available.

Top Products and Market Share

overview logo Key Offerings

  • CC846: A non-opioid pain therapeutic for chronic pain. Market share data is not publicly available as CC846 is currently in clinical development. Key competitors in the pain management market include companies developing opioids and non-opioid pain relievers, such as Pfizer (PFE) and Eli Lilly (LLY).
  • Flavor Ingredients: Novel flavor ingredients for the food and beverage industry. Market share data is not publicly available due to the proprietary nature of Chromocell's flavor compounds. Competitors include flavor houses such as Givaudan (GVDNY) and International Flavors & Fragrances (IFF).

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and intense competition. The flavor and fragrance industry is driven by consumer demand for innovative and appealing flavors and scents.

Positioning

Chromocell is positioned as an innovator in both the biopharmaceutical and flavor/fragrance industries. Its Chromovertu00ae technology gives it a competitive advantage in identifying novel drug targets and flavor compounds. They are a niche player compared to larger market incumbents.

Total Addressable Market (TAM)

The pain management market is estimated to be worth billions of dollars, with the global flavor and fragrance market also worth billions. Chromocell is positioned to capture a share of these markets through its innovative products. TAM estimates depend on the success of CC846 and commercialization of flavor ingredients. Estimates are often found in market reports which require paid subscriptions.

Upturn SWOT Analysis

Strengths

  • Proprietary Chromovertu00ae technology
  • Focus on non-opioid pain therapeutics
  • Innovation in flavor and fragrance discovery
  • Experienced scientific team

Weaknesses

  • Limited financial resources as a private company
  • Reliance on clinical trial success for drug development
  • Dependence on strategic partnerships for commercialization
  • Lack of publicly available data hinders full analysis

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion into new therapeutic areas
  • Growth in the flavor and fragrance market
  • Increased demand for non-addictive pain relievers

Threats

  • Regulatory hurdles for drug approval
  • Competition from established pharmaceutical companies
  • Patent challenges
  • Changes in consumer preferences in the flavor market

Competitors and Market Share

competitor logo Key Competitors

  • PFE
  • LLY
  • IFF
  • GVDNY

Competitive Landscape

Chromocell's competitive advantage lies in its proprietary technology platform. However, it faces significant competition from larger, well-established companies with greater resources.

Growth Trajectory and Initiatives

Historical Growth: Historical growth data is not publicly available.

Future Projections: Future growth projections are not publicly available, as the company is private. Analyst estimates are not available.

Recent Initiatives: Recent initiatives include continued clinical development of CC846 and expansion of its flavor ingredient portfolio.

Summary

Chromocell Therapeutics Corporation is a private company focused on innovative drug discovery and flavor ingredient development. Its proprietary technology offers a competitive advantage, but the company faces financial limitations and competition from larger players. Success hinges on clinical trial outcomes and strategic partnerships, but without public data, a full assessment is impossible. The company needs to secure adequate funding and navigate the complex regulatory environment for drug development.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • Industry reports
  • Press releases

Disclaimers:

Data is based on publicly available information and may be incomplete. Market share estimates are approximate. This analysis is for informational purposes only and should not be considered investment advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Chromocell Therapeutics Corporation

Exchange NYSE MKT
Headquaters Freehold, NJ, United States
IPO Launch date 2024-02-16
President, CEO, CFO, Treasurer, Secretary & Director Mr. Francis Knuettel II, M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 4
Full time employees 4

Channel Therapeutics Corporation, a clinical-stage biotech company, develops and commercializes new therapeutics to alleviate pain. It targets sodium ion-channel NaV1.7; and develops NaV blockers that target the body's peripheral nervous system. The company's lead compound is CC8464, which has completed Phase 1 clinical trials for the treatment of moderate-to-severe pain in erythromelalgia and idiopathic small fiber neuropathy. It also develops CT2000 as a topical agent for the treatment of both acute and chronic eye pain; and CT3000 to treat post operative pain with the use of nerve blocks. The company was Chromocell Therapeutics Corporation and changed its name to Channel Therapeutics Corporation in November 2024. Channel Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.